So the management is reliant on a big pharma to come along and fund the trials. When they look at the track record of this what do you think they may think? Clutching at straws I think, and not very confident of the EMA outcome. But at least the management and QUT have their salaries and fees guaranteed for another 6 months. They may need it as they should never get another job after this. But remember that if it all goes bust QUT still owns the rights. It will just refloat with a new company and start again.
TIS Price at posting:
24.5¢ Sentiment: Hold Disclosure: Held